近期，国家医保局公布一批应用药品追溯码打击回流药的典型案例。串换药品、非法购销药品、骗取医 保基金等违法违规行为在数字技术的追踪下纷纷现形。这既显示了科技手段赋能监管的成效，更传递出 我国严厉打击回流药的坚定决心。 回流药是指通过非法渠道回收已流出正规医药流通环节的药品，并将其重新流入市场的现象。一些不法 分子通过"医保取现""高价回收"等手段诱导参保人倒卖医保药品，有的药贩子还将过期药翻新、用真药 盒装假药再次销售，通过各种腾挪运作、移花接木的非法手段牟利。回流药不仅严重威胁群众用药安 全，还会侵蚀医保基金，扰乱市场秩序，对正规药品市场产生冲击。 过去受限于技术手段等原因，治理效果有限。目前，药品追溯码的推广应用正在改变这种局面。按照有 关规定，一盒药品只应有一次被最终销售扫码的记录，如果存在多次终端结算扫码记录，就可能是回流 药、假药或被串换销售。目前，"买药先扫码、卖药必扫码"的社会共识已基本形成，回流药的生存空间 进一步被压缩。 纵然利器在手，但回流药的治理并非一朝一夕之功。一方面，要提高违法成本，让不法分子心有所戒。 通过完善相关法律法规，明确倒卖回流药应负的法律责任，加大对不法分子的惩处力度，如采 ...

所谓回流药，主要指通过非法渠道回收、重新包装或篡改信息后再次销售的药品。这些药品往往来源不 明，脱离了正规流通环节和监管环节，不仅扰乱市场秩序，也给患者生命健康带来重大隐患。 新华社记者彭韵佳、徐鹏航 小小药片，连着每个人的生命安全，系着千家万户的健康福祉。近日，国家医保局公布部分应用药品追 溯码打击倒卖回流药骗取医保基金专项行动典型案例，展现了"码上监管"的新成效，更透出彻底斩断黑 色链条、从源头上治理回流药的决心。 严查！斩断回流药黑色链条 （新华社北京9月22日电） 现实中，药贩子收售回流药的手段隐蔽且恶劣：有的以返利为诱饵，引诱参保人出售医保药品，进行非 法逐利；有的批量式"洗白"，伪造票据为来路不明的药品"换个身份"；有的在拆解重组回流药过程中， 无视药品存储避光、冷藏等要求，甚至肆意混淆剂量规格与药品种类。在"零本万利"的驱动下，回流药 成了药贩子牟取暴利的工具，严重侵蚀医保基金，也让百姓用药安全风险陡增。 不过，高压态势下，仍有一些不法分子涉险牟利，让不合规药品流入百姓药盒。必须清醒认识到，彻底 斩断这一黑链条，绝非紧抓一个环节就能实现，需要各个环节拧紧"责任阀"：药企、医疗机构、零售药 店应严 ...

Group 1: National Healthcare Administration Updates - The National Healthcare Security Administration has announced the preliminary review results for the 2025 medical insurance directory and the commercial insurance innovative drug directory, with 534 out of 633 drug names passing the initial review [1] - A total of 121 drug names were approved for the commercial insurance innovative drug directory, which includes high-innovation drugs not yet included in the basic medical insurance directory [1] - The review results are a preliminary step, and the approved drugs will undergo further evaluation and negotiation before being officially included in the directories [1] Group 2: Drug Traceability in Qingdao - Qingdao has implemented a drug traceability code system, with 10.1 billion data entries collected, accounting for 26.5% of the total in the province [2] - The city has connected 4,268 retail pharmacies and 5,946 medical institutions to the traceability system, achieving over 99% and 90% scanning rates, respectively [2] - The traceability system aims to enhance drug safety and improve the supervision of medical insurance funds [2] Group 3: Drug Approvals and Clinical Trials - Heng Rui Medicine's application for the marketing license of Haqubopam Ethanolamine Tablets has been accepted by the National Medical Products Administration [3] - Fosun Pharma's application for the registration of Nadaplatin Injection has also been accepted, targeting various types of cancer [4] - Xingqi Eye Medicine has completed the first patient enrollment for the Phase II clinical trial of Voriconazole Eye Drops, aimed at treating fungal keratitis [5] - Haishi Ke has received approval for clinical trials of HSK47977 Tablets, a potential first-in-class drug for non-Hodgkin lymphoma [6] Group 4: Mergers and Acquisitions - Nanhua Biological is planning to acquire a 51% stake in Hunan Huize Biological Pharmaceutical Technology Co., which will become a subsidiary [7] - The acquisition aims to enhance Nanhua's capabilities in drug research and clinical evaluation [7] Group 5: Strategic Partnerships and Collaborations - East China Pharmaceutical's subsidiary has signed an exclusive commercialization agreement with Jiangsu Weikail, acquiring rights for the VC005 oral formulation in mainland China [8] - The agreement includes an upfront payment of 50 million RMB and potential milestone payments up to 180 million RMB [8] - KQ Bio plans to sign a collaborative research agreement with Huazhong Agricultural University, involving four projects with a total payment of 4.9 million RMB [9]

Macro Dynamics - The State Administration for Market Regulation issued the "Compliance Guidelines for Charging Behavior of Online Trading Platforms," aiming to standardize the fees charged by platforms to operators, advocating for reduced burdens on operators and enhanced compliance self-discipline [2] Healthcare Sector - The National Healthcare Security Administration reported a case of illegal resale of medical insurance drugs, where a community health service station was found to have repeated billing for drugs, leading to the recovery of 3,678 yuan from the insurance fund and a fine of 7,356 yuan [3] Financial Sector - The Guangdong Provincial Financial Management Bureau and five other departments released the "Implementation Rules for Loan Interest Subsidies for Manufacturing and High-tech Enterprises," specifying a negative list for loan project approvals [4] - Shanghai Bank was fined over 29.21 million yuan by the central bank for issues arising between 2020 and 2021, which have since been rectified [7] - The Bank of Communications issued the world's first offshore bond for the Shanghai Free Trade Zone with a coupon rate of 1.85% and a term of three years [8] Market Data - As of August 1, U.S. stock indices collectively fell, with the Dow down 1.23%, the Nasdaq down 2.24%, and the S&P 500 down 1.6%, with significant declines in popular tech stocks [9] - The Nasdaq Golden Dragon China Index fell by 1.82%, with major Chinese concept stocks also experiencing declines [10] Company Dynamics - Zhang Jian was approved to serve as the general manager of China Post Insurance Asset Management Co., Ltd. [11] - Tim Cook became the longest-serving CEO of Apple, surpassing Steve Jobs with a tenure of 5,091 days [12] - Didi Chuxing collaborated with police to combat illegal ride-hailing software, leading to the arrest of a suspect involved in creating such software [13] - China FAW Group reported that in July 2025, its vehicle sales exceeded 252,400 units, a year-on-year increase of 6.5%, with significant growth in its self-owned and new energy vehicle sales [14]

Core Viewpoint - The National Healthcare Security Administration (NHSA) has launched a nationwide campaign to combat fraud and illegal activities in the pharmaceutical sector using drug traceability codes, resulting in multiple cases of illegal resale of reimbursed drugs being uncovered [1][14]. Group 1: Case Summaries - In Ulanqab City, Inner Mongolia, a community health service station was found to have sold drugs with duplicate traceability codes, leading to the recovery of 3,678 yuan in healthcare funds and a fine of 7,356 yuan [2]. - In Dezhou City, Shandong Province, a village health clinic was discovered to have sold drugs with traceability codes that had been reimbursed multiple times, resulting in a three-month suspension of its healthcare service agreement [3]. - A health clinic in Dazhu District, Chongqing, was found to have engaged in illegal drug exchanges, leading to a six-month suspension of its healthcare service agreement and penalties for the responsible personnel [4]. - A clinic in Suining City, Sichuan Province, was implicated in reselling drugs that had been previously reimbursed, resulting in penalties and recovery of healthcare funds [5]. - In Longli County, Guizhou Province, a health service was found to have resold drugs obtained through fraudulent means, leading to the recovery of 1,521.67 yuan in healthcare funds [7]. - A pharmacy in Nanyang City, Henan Province, was involved in the resale of drugs with duplicate traceability codes, resulting in the recovery of 67,200 yuan in healthcare funds and administrative penalties [8]. - In Wuzhong City, Ningxia, a pharmacy was found to have resold drugs that had been reimbursed, leading to a three-month suspension of its healthcare service agreement [9]. - Two insured individuals in Hangzhou, Zhejiang Province, were found to have illegally resold drugs, resulting in a loss of 439,854.73 yuan in healthcare funds [10]. - In Shuangyashan City, Heilongjiang Province, an individual was found to have resold drugs, leading to the recovery of 55,269.2 yuan in healthcare funds [11][12]. - An insured individual in Quanzhou City, Fujian Province, was found to have resold drugs, resulting in a loss of 5,139.45 yuan in healthcare funds [13]. Group 2: Impact of Drug Traceability Codes - The implementation of drug traceability codes has led to the collection of 53.098 billion drug traceability codes, significantly enhancing the monitoring and regulation of drug sales [13][14]. - The success of the traceability system is attributed to the collaborative efforts of regulatory bodies, pharmaceutical companies, and the active participation of the public in verifying drug authenticity [14].

Core Viewpoint - The National Healthcare Security Administration (NHSA) has announced ten typical cases of fraud and illegal activities in the pharmaceutical sector, highlighting the ongoing efforts to combat drug-related fraud through the use of drug traceability codes [1][2] Group 1: Fraud Cases - The ten typical cases involve activities such as the resale of medical insurance drugs and the swapping of drugs across various regions in China, including Inner Mongolia, Shandong, Chongqing, Sichuan, Guizhou, Henan, Ningxia, Zhejiang, Heilongjiang, and Fujian [1] - Specific cases include the resale of medical insurance drugs by community health service stations and pharmacies, with notable instances in Ulanqab, Dezhou, Dazhu, and other locations [1] Group 2: Role of Drug Traceability Codes - Drug traceability codes have played a crucial role in identifying fraudulent activities, with over 53 billion drug traceability codes collected nationwide [2] - An example includes the Ulanqab community health service station, where 72 drug traceability codes were found to have duplicate settlements, leading to an investigation that uncovered the resale of drugs by medical staff [2] Group 3: Impact on Insurance Funds - The fraudulent activities have resulted in significant losses to the medical insurance fund, with one case in Hangzhou causing a loss of approximately 439,854.73 yuan due to the illegal resale of drugs by insured individuals [2] - The NHSA emphasizes the importance of compliance with drug procurement and settlement processes to protect the integrity of the medical insurance system [2]

Core Viewpoint - The National Medical Insurance Administration, in collaboration with relevant departments, has launched a nationwide special action to combat fraud and illegal activities in the pharmaceutical sector using drug traceability codes as a key tool [1]. Summary by Sections - **Case Examples**: Eight typical cases of fraud were announced, including a significant case involving a pharmacy in Lanzhou, Gansu Province, which was found to be reselling medical insurance drugs and illegally profiting from the medical insurance fund [2][3]. - **Details of Fraudulent Activities**: The Lanzhou pharmacy was discovered to have illegally collected medical insurance cards from local residents, processed fraudulent transactions, and resold high-value drugs, including cancer treatment medications. A total of 1,124 boxes of drugs across 135 varieties were seized during the inspection [2][3]. - **Consequences for Offenders**: The pharmacy's medical insurance service agreement was terminated, and the legal representative received a penalty of 12 points against their medical insurance payment qualifications. Other cases involved similar fraudulent activities across various provinces, including Wuhan, Changsha, and Xi'an, with issues such as falsified prescriptions and excessive drug dispensing [3][4]. - **Regulatory Actions**: The cases have been referred to law enforcement and health regulatory agencies for further action. The National Medical Insurance Administration emphasized the importance of drug traceability codes as unique identifiers for each drug, urging all medical insurance institutions to comply with procurement and settlement regulations [4].

Core Viewpoint - The article discusses the upcoming provincial-level inspections of medical insurance funds in Hunan, emphasizing the importance of safeguarding these funds for the benefit of insured individuals and the overall healthcare system [2][5]. Group 1: Overview of Inspections - The Hunan Provincial Medical Insurance Bureau announced a special inspection of medical insurance funds from July to September 2025, covering the usage from January 1, 2023, to June 30, 2025 [2]. - The inspections aim to enhance the supervision of medical insurance funds, with a focus on high-risk areas and behaviors, including fraudulent practices in medical institutions and retail pharmacies [7][10]. Group 2: Inspection Methodology - The inspections will utilize a "no prior notice" approach, allowing for unannounced checks at designated medical institutions [9]. - Key features of the inspections include a cross-checking mechanism, high professional standards, and the formation of specialized teams to improve efficiency [10]. Group 3: Targeted Areas of Concern - Specific areas of focus include fraudulent hospital admissions, excessive hospitalization rates, and violations related to prescription transfers and drug procurement [10][11]. - Retail pharmacies will be scrutinized for fraudulent practices such as falsifying prescriptions and engaging in drug trafficking [11]. Group 4: Broader Regulatory Context - The article highlights ongoing efforts to combat medical insurance fraud, including recent cases of significant fraud involving millions in claims [15]. - The introduction of smart regulatory measures, such as the mandatory scanning of drug traceability codes for insurance settlements, aims to reduce fraudulent activities [16]. Group 5: Involvement of Third Parties - Third-party organizations are increasingly involved in the oversight of medical insurance fund usage, enhancing the regulatory framework through data-driven approaches [17].

Group 1 - The National Medical Insurance Administration has announced the full implementation of drug traceability codes starting July 1, which will serve as an "electronic ID" for drugs, requiring medical institutions to record and trace information throughout the entire process of drug payment [1][2] - Medical institutions and retail pharmacies must accurately collect and verify drug traceability codes and upload this information to a national unified medical insurance information platform and drug traceability system [1][2] - A special action has been initiated to combat fraud and illegal activities in the pharmaceutical sector, with the first phase of inspections already completed and a new round of checks scheduled for August [1] Group 2 - The traceability code is a key factor in establishing verification and acceptance systems for drug procurement, and institutions are urged to avoid accepting or trading in returned drugs [2]

Core Viewpoint - The National Medical Products Administration (NMPA) has launched a "Clean Source" action to combat illegal activities in the pharmaceutical distribution sector, ensuring public health and safety amid rising issues like counterfeit drugs and illegal online sales [1][2][3]. Group 1: Regulatory Actions - The "Clean Source" action was initiated in April 2023, focusing on eliminating risks and illegal practices in drug distribution, with a commitment to continue until November 2025 [2][5]. - The NMPA has emphasized the importance of cross-departmental collaboration and the use of digital monitoring tools, such as drug traceability codes, to enhance regulatory effectiveness [6][7]. Group 2: Case Examples - Five typical cases of violations were reported, including illegal procurement and sales of drugs, with penalties ranging from fines to the revocation of operating licenses [3][4]. - Specific cases include a pharmacy in Guangdong fined 1.3 million yuan for illegal drug procurement and a pharmacy in Jiangxi penalized for selling drugs without proper qualifications [3][4]. Group 3: Industry Impact - The initiative aims to establish a transparent and compliant pharmaceutical distribution system, promoting industry compliance and enhancing public trust in drug safety [3][6]. - The focus on digital upgrades in drug monitoring is expected to shift regulatory practices from reactive to proactive, improving overall drug safety [6][7].